These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8757435)

  • 1. Reactivity of Argentine serum samples against synthetic V3-based HIV-1 peptides.
    Pampuro SE; Calarota SA; Marquina SA; Rabinovich RD; Libonatti OV
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):527-8. PubMed ID: 8757435
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroreactivity to HIV-1 V3 subtypes A to H peptides of Argentinian HIV-positive sera.
    Devito C; Levi M; Hinkula J; Fernandez Medina RD; Libonatti O; Wigzell H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Feb; 17(2):156-9. PubMed ID: 9473017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti V3 antibodies in HIV-1 positive human sera.
    Gómez CE; López-Campistrous AE; Duarte CA
    J Virol Methods; 1998 Mar; 71(1):7-16. PubMed ID: 9628216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivity of AIDS patient sera with a peptide derived from HIV type 1NY5 glycoprotein 120 V3 loop and consensus sequence of collagens.
    Metlas R; Skerl V; Pongor S; Colombatti A; Veljković V
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1425-6. PubMed ID: 7888196
    [No Abstract]   [Full Text] [Related]  

  • 7. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal antibodies to HIV-1 envelope domains: No correlation with HIV-1 vertical transmission in patients from Argentina.
    Calarota SA; Libonatti OV
    Scand J Immunol; 2000 Sep; 52(3):292-7. PubMed ID: 10972906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of synthetic peptides for the detection of antibodies against human immunodeficiency virus].
    Lottersberger J; Salvetti JL; Tonarelli G
    Rev Argent Microbiol; 2003; 35(3):149-55. PubMed ID: 14587377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities.
    Riley JP; Pestano GA; Hosford K; Francis C; Xie JM; Mugyenyi P; Kataaha P; Katongole-Mbidde E; Anokbonggo WW; Guyden J
    Arch Virol; 1995; 140(8):1393-404. PubMed ID: 7544970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantage of dimeric peptide antigens in serodiagnosis of HIV-1 infection.
    Gokulan K; Tripathi SP; Rao DN
    Microbiol Immunol; 1997; 41(3):215-20. PubMed ID: 9130233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuity and discontinuity in the anti-V3 IgG response of human immunodeficiency virus type 1-infected persons in a cross-sectional and longitudinal study using synthetic peptides.
    Lawoko A; Johansson B; Dash R; Falck L; Dietrich U; Pipkorn R; Nilehn B; Blomberg J
    J Infect Dis; 1995 Sep; 172(3):682-90. PubMed ID: 7658059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1).
    Yu T; Bai Y; Dierich MP; Chen YH
    Microbiol Immunol; 2000; 44(2):105-10. PubMed ID: 10803497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.
    Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G
    AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
    Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restriction of serum antibody reactivity to the V3 neutralizing domain of HIV gp120 with progression to AIDS.
    Page M; Vella C; Corcoran T; Dilger P; Ling C; Heath A; Thorpe R
    AIDS; 1992 May; 6(5):441-6. PubMed ID: 1616648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
    Boudet F; Keller H; Kieny MP; Thèze J
    Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presentation of HIV V3 loop epitopes for enhanced antigenicity, immunogenicity and diagnostic potential.
    Fontenot JD; VanCott TC; Parekh BS; Pau CP; George JR; Birx DL; Zolla-Pazner S; Gorny MK; Gatewood JM
    AIDS; 1995 Oct; 9(10):1121-9. PubMed ID: 8519447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail.
    Rubinstein A; Goldstein H; Pettoello-Mantovani M; Cryz SJ
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S149-53. PubMed ID: 7865291
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.